ARQT News and Press, Arcutis Biotherapeutics Inc. From 11/14/22

Arcutis Biotherapeutics, Inc. (ARQT) Q3 2022 Earnings Conference Call November 08, 2022, 17:00 ET Company Participants Eric McIntyre - Head, IR Todd Watanabe - President, CEO & Director Kenneth Lock - Chief Commercial Officer Patrick Burnett - SVP & C...

Arcutis Biotherapeutics press release ( NASDAQ: ARQT ): Q3 GAAP EPS of -$1.89 misses by $0.01 . Revenue of $0.73M beats by $0.07M . Cost of sales for the quarter ended September 30, 2022 were $0.3 million driven primarily by the amortization of a milesto...

Launched ZORYVE ® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in adolescents and adults in mid-August, achieving net revenues of $0.7 million for the third quarter ZORYVE now covered by one of the top pharmacy benefit managers and a large national health ...

WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 5:00 p.m...

Findings presented at the annual Fall Clinical Dermatology Conference Survey found that path to diagnosis for people with seborrheic dermatitis (average of 3.6 years) substantially longer than estimated by physicians (average of 1.5 years) Prior to diagnosis, 71% of individuals wi...

Summary Arcutis Biotherapeutics shares are down 15% year to date. Approval of Zoryve topical cream in plaque psoriasis with reasonable price point provides a degree of derisking. A confluence of phase 3 readouts are expected later this quarter and into year-end for multiple in...

Arcutis Biotherapeutics ( NASDAQ: ARQT ) said that top-line phase 3 results for roflumilast foam in scalp and body psoriasis met their co-primary endpoints . Results showed that at week 8, 67.3% of patients treated with roflumilast, a once-daily, non-steroidal top...

Study met both co-primary endpoints and all secondary endpoints At week eight, 67.3% of individuals treated with roflumilast foam achieved Scalp-Investigator Global Assessment (S-IGA) Success compared to 28.1% of individuals treated with vehicle At week eight, 46.5% of individuals...

Roflumilast cream showed higher efficacy compared to vehicle in both Phase 3 studies on the primary efficacy endpoint of Investigator Global Assessment (IGA) success, with 40% of roflumilast cream treated patients achieving IGA success at eight weeks Roflumilast cream also dem...

Summary Shares of dermatology biopharma Arcutis Biotherapeutics, Inc. fell 16% the day after receiving its first FDA approval for ZORYVE (roflumilast) in the treatment of plaque psoriasis. The market seemed to be anticipating a secondary offering, which was executed three days lat...